Lecap Asset Management Ltd. acquired a new stake in shares of Chemed Co. (NYSE:CHE – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,133 shares of the company’s stock, valued at approximately $1,130,000.
Several other hedge funds have also recently made changes to their positions in the company. UMB Bank n.a. increased its holdings in shares of Chemed by 300.0% in the fourth quarter. UMB Bank n.a. now owns 52 shares of the company’s stock valued at $28,000 after purchasing an additional 39 shares during the period. Trust Co. of Vermont acquired a new position in Chemed in the 4th quarter worth approximately $34,000. GAMMA Investing LLC raised its position in Chemed by 60.5% during the 3rd quarter. GAMMA Investing LLC now owns 138 shares of the company’s stock worth $83,000 after buying an additional 52 shares during the last quarter. Sound Income Strategies LLC purchased a new stake in shares of Chemed in the 3rd quarter valued at $201,000. Finally, Farther Finance Advisors LLC boosted its holdings in shares of Chemed by 2,314.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 338 shares of the company’s stock valued at $203,000 after acquiring an additional 324 shares during the last quarter. 95.85% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of research analysts recently issued reports on CHE shares. StockNews.com upgraded shares of Chemed from a “hold” rating to a “buy” rating in a research report on Saturday, November 30th. Royal Bank of Canada decreased their price objective on Chemed from $697.00 to $633.00 and set an “outperform” rating for the company in a report on Tuesday, November 5th.
Chemed Stock Down 0.6 %
Shares of Chemed stock opened at $550.53 on Friday. Chemed Co. has a twelve month low of $512.12 and a twelve month high of $654.62. The business has a 50-day moving average price of $543.62 and a 200 day moving average price of $564.38. The firm has a market cap of $8.29 billion, a PE ratio of 27.82, a P/E/G ratio of 2.19 and a beta of 0.48.
Insider Activity at Chemed
In other Chemed news, VP Brian C. Judkins acquired 145 shares of the business’s stock in a transaction on Monday, December 30th. The stock was bought at an average price of $519.50 per share, for a total transaction of $75,327.50. Following the acquisition, the vice president now owns 1,678 shares in the company, valued at approximately $871,721. The trade was a 9.46 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Spencer S. Lee sold 732 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $575.62, for a total value of $421,353.84. Following the transaction, the executive vice president now owns 18,287 shares in the company, valued at approximately $10,526,362.94. This represents a 3.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.32% of the stock is owned by corporate insiders.
Chemed Profile
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
Further Reading
- Five stocks we like better than Chemed
- What Are Some of the Best Large-Cap Stocks to Buy?
- IBM’s AI Bet Pays Off—What’s Next for Investors?
- Airline Stocks – Top Airline Stocks to Buy Now
- 3 Reasons to Treat AMD’s Drop as an Entry Opportunity
- Investing in the High PE Growth Stocks
- Qualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.